Ozette, a Seattle, WA-based technology-driven life sciences startup engineering a transformative leap in cell discovery and annotation of the human immune system, announced that it raised $26 million in Series A funding.
The round was led by Madrona Ventures, other participating investors include Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners, and Duke University.
The new funding will fuel company growth and enable Ozette to expand its capabilities across a multiomic platform, integrating single-cell proteomics and transcriptomics.
A new state-of-the-art immunology lab in development will soon offer another asset and avenue for partners to leverage Ozette’s technology, further enabling vertically integrated, automated analysis for immune insights.
Company: Ozette Technologies, Inc.
Round: Series A
Funding Month: July 2022
Lead Investors: Madrona Ventures
Additional Investors: Cercano Management (formerly Vulcan Capital), M12, Microsoft’s venture fund, Alexandria Venture Investments, OCV Partners, and Duke University.
Company Website: https://ozette.com/
Software Category: immunotherapy
About the Company: Founded in late 2020, Ozette was spun-out from the Fred Hutchinson Cancer Center and incubated at the Allen Institute for AI. Ozette Technologies, Inc. is engineering a transformative leap in cell discovery and annotation of the human immune system. The Seattle-based (remote-first) life sciences technology startup is building a groundbreaking high-resolution, intelligent, single-cell immune monitoring platform and corpus of high-resolution data leveraging its novel AI technologies. Ozette’s interdisciplinary team is made up of a deep bench of scientists, engineers, and designers with a wide range of experience spanning Genentech, Google, Microsoft, Amazon, Airbnb, and more. Ozette’s team also includes leaders and pioneers in the field of medical research and single cell analysis, including its founders: physician Ali Ansary, and scientists Greg Finak, Evan Greene, and Raphael Gottardo.